Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Roivant Sciences (ROIV) Stock Price & Analysis

754 Followers

ROIV Stock Chart & Stats

$39.53-$0.46(-1.15%)
At close: 4:00 PM EST
$35$37.5$40Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$39.16 - $39.88
52-Week Range
$19.96 - $42.50
Previous Close
$39.99
Volume
N/A
Average Volume (3M)
7.56M
Market Cap
$28.98B
Enterprise Value
$22.91B
Total Cash (Recent Filing)
$4.21B
Total Debt (Recent Filing)
$106.57M
Price to Earnings (P/E)
―
Beta
0.80
Next Earnings
Feb 15, 2027 (Est.)
EPS Estimate
-0.29
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Successful LISRAYA Commercialization

Rapid early uptake for LISRAYA demonstrates meaningful demand for a targeted treatment in an underserved rare disease. Broad prescriber adoption, patient starts, and supportive early payer access create a commercial foundation that can support recurring revenue growth beyond the initial launch period.

Pipeline Clinical Progress

Positive late-stage data across brepocitinib and mosliciguat diversify Roivant’s growth prospects beyond its initial commercial product. Potential NIU approval and continued pulmonary hypertension development could expand the addressable market and create multiple future revenue drivers.

Strong Balance Sheet And Liquidity

Very low leverage and substantial liquidity provide Roivant with flexibility to fund clinical programs, commercialization, and potential indication expansion without relying heavily on debt. This capitalization also gives the company greater capacity to absorb development setbacks while advancing its pipeline.

Bears Say

Deep Ongoing Operating Losses

The current revenue base remains far too small to cover operating costs, producing deeply negative profitability despite strong gross margins. Sustained losses reduce earnings visibility and require successful commercialization or pipeline outcomes before the business can demonstrate durable operating leverage.

Negative Cash Generation

Roivant is still consuming cash rather than funding operations internally, which keeps execution dependent on its liquidity reserve and future product success. Although the latest burn improved, continued negative cash flow could constrain capital allocation if commercialization or clinical milestones take longer than expected.

Regulatory Uncertainty For IMVT-1402

Unresolved FDA requirements create uncertainty around the scale, timing, and cost of IMVT-1402’s next development stage. Until regulatory alignment is reached, the program’s path to approval remains difficult to forecast, potentially delaying a major pipeline opportunity and increasing execution risk.

Roivant Sciences News

ROIV FAQ

What was Roivant Sciences’s price range in the past 12 months?
Roivant Sciences lowest stock price was $19.96 and its highest was $42.50 in the past 12 months.
What is Roivant Sciences’s market cap?
Roivant Sciences’s market cap is $28.98B.
When is Roivant Sciences’s upcoming earnings report date?
Roivant Sciences’s next earnings report is estimated for Feb 15, 2027 (not yet confirmed), which is in 93 days.
How were Roivant Sciences’s earnings last quarter?
Roivant Sciences released its earnings results on Nov 09, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.367 by $0.097.
Is Roivant Sciences overvalued?
According to Wall Street analysts Roivant Sciences’s price is currently Undervalued.
Does Roivant Sciences pay dividends?
Roivant Sciences does not currently pay dividends.
What is Roivant Sciences’s EPS estimate?
Roivant Sciences’s EPS estimate is -0.29.
How many shares outstanding does Roivant Sciences have?
Roivant Sciences has 724,561,460 shares outstanding.
What happened to Roivant Sciences’s price movement after its last earnings report?
Roivant Sciences reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.367. Following the earnings report the stock price went up 4.604%.
Which hedge fund is a major shareholder of Roivant Sciences?
Hedge funds hold Roivant Sciences shares: the largest hedge-fund position in Roivant Sciences is 71,886,399 shares, and hedge funds increased their holdings by 9.8M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology